Costs and cost-effectiveness of colorectal cancer prevention and therapy.

摘要: For cancer, the evaluation of new prevention and therapeutic strategies has traditionally focused almost exclusively on safety efficacy. However, comparison costs cost-effectiveness medical interventions is increasingly being recognized as an important goal. Cancer care a prime target for scrutiny because US cancer treatment consumes over $40 billion per year or approximately 12% total health expenditures. Colorectal (CRC) $6.5 and, among malignancies, second only to breast at $6.6 year. Nonetheless, there are relatively few published studies addressing economic consequences CRC. This review describes strengths limitations major types analyses, well existing literature CRC treatment. Although standard approaches both screening appear cost-effective when compared with no intervention, relative different screening, treatment, posttherapeutic surveillance remains uncertain. As databases information systems able integrate comprehensive cost data grow in availability sophistication, it should become easier compare impact various terms traditional outcomes. Over next years, results first clinical trials that prospectively assess end points anticipated; experience resulting from these efforts stimulate enhance future studies.